Top Page
PAVmed
(NASDAQ:PAVM)
PAVmed (PAVM) vs. SPDR S&P 500 ETF (SPY)
PAVmed Business Overview & Revenue Model
PAVmed Earnings Call Summary
PAVmed Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.00K | 3.00M | 2.45M | 377.00K | 500.00K | 0.00 |
| Gross Profit | -194.00K | -3.04M | -3.97M | -3.24M | -85.00K | 0.00 |
| EBITDA | 1.61M | 29.67M | -75.74M | -99.50M | -55.90M | -23.33M |
| Net Income | 3.10M | 39.79M | -64.17M | -88.98M | -50.35M | -34.28M |
Balance Sheet | ||||||
| Total Assets | 38.07M | 30.66M | 33.12M | 53.98M | 86.98M | 19.78M |
| Cash, Cash Equivalents and Short-Term Investments | 3.10M | 1.19M | 19.64M | 42.75M | 79.25M | 17.52M |
| Total Debt | 9.28M | 31.86M | 48.73M | 36.64M | 0.00 | 14.96M |
| Total Liabilities | 12.28M | 37.69M | 57.14M | 43.05M | 7.56M | 20.25M |
| Stockholders Equity | 35.78M | -2.50M | -53.83M | -9.68M | 61.67M | 1.90M |
Cash Flow | ||||||
| Free Cash Flow | -3.58M | -33.61M | -52.28M | -72.53M | -42.06M | -21.97M |
| Operating Cash Flow | -3.56M | -33.55M | -52.04M | -70.98M | -40.59M | -21.91M |
| Investing Cash Flow | -21.00K | -16.18M | 758.00K | -4.74M | -3.72M | -55.00K |
| Financing Cash Flow | 5.92M | 31.28M | 31.17M | 38.21M | 104.31M | 33.01M |
PAVmed Technical Analysis
PAVmed Risk Analysis
PAVmed Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.91M | -0.62 | 20.03% | ― | -99.28% | -46.17% | |
49 Neutral | $7.57M | -0.24 | -197.26% | ― | -2.47% | 91.23% | |
47 Neutral | $6.92M | -1.47 | -84.30% | ― | -20.05% | 41.89% | |
46 Neutral | $6.48M | -0.39 | -207.19% | ― | -5.19% | -0.81% | |
46 Neutral | $9.31M | -0.41 | -220.42% | ― | -41.03% | 35.71% | |
44 Neutral | $4.92M | -0.08 | -62.12% | ― | -87.84% | 29.16% |
PAVmed Corporate Events
On February 3, 2026, PAVmed raised $30 million through the issuance of newly designated Series D Convertible Preferred Stock to accredited investors, together with warrants that could provide up to an additional $30 million in preferred equity upon certain conditions, and simultaneously issued a new $15 million senior secured note maturing in February 2029 to an existing investor. Using the proceeds, the company redeemed all outstanding Series C Convertible Preferred Stock and refinanced and fully retired its prior convertible debt, leaving approximately $7.7 million in net cash for working capital, and positioning its capital structure to consist primarily of common equity and long-term debt once the Series D converts, subject to stockholder approval at a special meeting expected by April 30, 2026. PAVmed has secured voting commitments from holders of roughly a quarter of its common stock in favor of the conversion proposal, and management framed the transaction as a transformational clean-up of a longstanding capital structure overhang that strengthens the balance sheet, clarifies ownership ahead of anticipated value catalysts at Lucid Diagnostics and Veris Health, and enhances the company’s flexibility to pursue additional commercial opportunities while it continues to hold 31 million Lucid shares on its balance sheet.
The most recent analyst rating on (PAVM) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On January 21, 2026, PAVmed Inc. announced it had regained compliance with the Nasdaq Capital Market’s $1 minimum bid price requirement for continued listing, following a period beginning January 23, 2025, when its stock had traded below the $1 threshold for at least 30 consecutive business days. Nasdaq determined that between January 2 and January 19, 2026, PAVmed’s closing bid price had been at or above $1 per share, restoring the company’s compliance with listing rules and reducing the immediate risk of delisting, a development that stabilizes its market position and offers greater reassurance to investors and other stakeholders.
The most recent analyst rating on (PAVM) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On December 30, 2025, PAVmed Inc. announced that it will implement a 1-for-30 reverse stock split of its common stock, effective January 2, 2026, following shareholder approval at a special meeting on December 5, 2025 and board approval of the ratio on December 8, 2025. The move, which also reduces authorized common shares from 250 million to 25 million, is aimed at lifting PAVmed’s share price above Nasdaq’s $1.00 minimum bid requirement after a prolonged period of non-compliance, and will proportionately adjust outstanding options, convertible securities and equity plan share reserves while rounding up any fractional shares to the nearest whole share; the company’s Nasdaq ticker will remain PAVM, though its CUSIP number will change.
The most recent analyst rating on (PAVM) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On December 5, 2025, PAVmed Inc. held a special meeting where stockholders approved an amendment to the company’s certificate of incorporation. This amendment allows for a reverse stock split at a ratio between 1-for-10 and 1-for-30, and a reduction in authorized common stock from 250 million to 25 million shares. The board of directors has yet to decide the specific ratio for the reverse split but plans to implement the changes soon by filing with the Delaware Secretary of State.
The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
On November 13, 2025, PAVmed Inc. announced a business update and financial results for the third quarter of 2025. The company highlighted significant advancements, including Veris Health’s commercial phase launch with The Ohio State University James Cancer Hospital and the relaunch of its implantable physiological monitor development. PAVmed also signed a letter of intent to license a new endoscopic imaging technology from Duke University, aiming to expand its innovation pipeline. Lucid Diagnostics reported $1.2 million in revenue from EsoGuard tests and received unanimous support for Medicare coverage, strengthening its financial position with a public stock offering. The company reported a GAAP net loss of $6.3 million for the quarter, with cash reserves increasing to $3.1 million.
The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.